Last reviewed · How we verify

Cyramza (RAMUCIRUMAB)

Eli Lilly · FDA-approved approved Monoclonal antibody Quality 60/100

Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.

Cyramza (ramucirumab) is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist developed by Eli Lilly and Company. It works by blocking the VEGFR2 receptor, which is involved in the growth and spread of cancer cells. Cyramza is approved to treat various types of cancer, including stomach, liver, colon, and lung cancers. The drug is still patented and has a half-life of 14 days. Key safety considerations include hypertension and bleeding risks.

At a glance

Generic nameRAMUCIRUMAB
SponsorEli Lilly
Drug classVascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]
TargetVascular endothelial growth factor receptor 2
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2014
Annual revenue900

Mechanism of action

Ramucirumab is VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType
Biologic Exclusivity

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings